Search Results
Your search for The matches 35203 pages
Showing 1 - 50Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows
In a case presentation published in The New England Journal of Medicine, targeted treatment was successful for chimeric antigen receptor (CAR)-positive peripheral T-cell lymphoma developed after CAR T-cell therapy for multiple myeloma. Using advanced genomic, phenotypic, and functional profiling...
Racial and Ethnic Disparities in Guideline-Concordant Pancreatic Cancer Care Among Older Adults
In a study published in the Journal of Clinical Oncology Practice, Herb et al investigated racial and ethnic disparities in the receipt of guideline-concordant care among older adults with pancreatic cancer. Using data spanning 15 years, the researchers examined whether differences in treatment...
Bacterial Decolonization to Manage Acute Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma
Based on the results of a single-center phase III Chinese trial, which were published by Liao et al in JAMA Oncology, bacterial decolonization therapy with the antibiotic mupirocin may be an effective and cost-efficient strategy for alleviating severe acute radiation-induced oral mucositis in...
Study Finds Weather Disasters Increase Risk for U.S. Drug Supply Chain Disruption
In 2024, Hurricane Helene triggered a nationwide shortage of the country’s intravenous (IV) fluids after damaging a facility in North Carolina. A similar IV fluid shortage was caused when Hurricane Maria hit Puerto Rico in 2017. In a recent, nationwide study led by the American Cancer Society...
Smoldering Multiple Myeloma: How the Guidance Is Changing
Clinical trials have sought to determine the benefit of treating the precursors of multiple myeloma, but as the phenotypes and genomics of this entity are becoming better delineated, the wisdom of early intervention has remained confusing for clinicians. At the 2025 Debates and Didactics in...
Advancing Geriatric Oncology: A Personal and Professional Journey
I would like to begin by sharing a bit of my journey in geriatric oncology. Often, we do not hear the origin stories behind our professional paths, and I believe it is important to reflect on them. I have spent my entire academic career at Wake Forest University School of Medicine, where I arrived...
Can Beta Blockers Help Halt the Progression of Triple-Negative Breast Cancer?
Researchers have identified a molecular biomarker in triple-negative breast cancers that may inform when beta blockers can play a role in “switching off” tumor progression. These findings were published by Lam et al in Science Signaling. When stress hormones are released by the body’s nervous...
Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types
Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, according to findings published in Nature. In exploring the role of perineural invasion and...
Nivolumab Plus RP1 Shows Durable Responses in Advanced Melanoma After PD-1 Inhibitor Resistance
Nivolumab in combination with RP1 (vusolimogene oderparepvec), a herpes simplex virus type 1–based oncolytic immunotherapy, showed activity in patients with advanced melanoma who experienced disease progression on standard anti‒PD-1‒based immunotherapy, according to findings from the phase I/II...
Identification of FAP-Expressing Tumors With Radiotracer
In a German single-center phase II trial reported in The Lancet Oncology, Pabst et al found that use of the fibroblast activation protein α (FAP)–directed radiotracer Ga-68–FAPi-46 for positron-emission tomography-computed tomography (PET-CT) has shown promising ability to identify FAP-expressing...
Adagrasib vs Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C–Mutated NSCLC
As reported in The Lancet by Barlesi et al, the phase III KRYSTAL-12 trial has shown a significant progression-free survival benefit with adagrasib over docetaxel in patients with previously treated locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC). Study Details...
Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?
Rechallenge with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) after grade 1 interstitial lung disease (ILD) appeared to be safe in a diverse real-world population, including many patients with breast cancer, as presented during the 2025 ASCO Annual Meeting.1 The ...
Rural and Urban Differences in Prostate Cancer Recurrence
In a study reported in JAMA Network Open, Balmaceda et al found that rural patients in North Carolina with newly diagnosed prostate cancer were more likely to experience biochemical recurrence than were urban patients. Study Details This cohort study used data from the North Carolina Prostate...
Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction
Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpretation of mammograms with an uncertainty quantification. According to study findings published in...
Friends of Cancer Research Advances Work to Improve Interpretation of Interim OS Data in Oncology Trials
Friends of Cancer Research (Friends) launched the next phase of an initiative to improve how to interpret interim overall survival (OS) data in oncology clinical trials. Building on discussions during the Friends 2024 Annual Meeting, this new effort focuses on developing practical frameworks and...
Patient and Health-Care Professional Groups Express Support for Bipartisan Clinical Trial Bill
More than 100 organizations representing millions of patients with serious health conditions and health-care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz...
New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss
A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss (AIBL) as a guide for osteoporosis specialists and oncologists. This position statement acts as an update on...
Metastatic Colorectal Cancer: PROs With Sotorasib and Panitumumab vs Standard of Care
In an analysis from the phase III CodeBreaK 300 study reported in The Lancet Oncology, Modest et al found that sotorasib and panitumumab were associated with better patient-reported outcomes (PROs) than standard of care (SOC) with trifluridine plus tipiracil or regorafenib in patients with KRAS...
Locoregionally Advanced Nasopharyngeal Carcinoma: Comparison of Regimens Following Induction Chemotherapy
In a Chinese phase III trial reported in JAMA Oncology, Xue et al found that sequential chemoradiotherapy (SCRT) was noninferior to induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) in terms of failure-free survival in patients with locoregionally advanced nasopharyngeal...
Can Autoimmune Diseases Increase the Risk of Digestive System Cancer?
In a systematic review and meta-analysis published in the journal eClinicalMedicine, Reizner et al highlighted bias-minimized insights into the associations between autoimmune diseases, such as celiac disease, systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes, and the risk of...
Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Effect of Hippocampal Avoidance in Prophylactic Cranial Irradiation in SCLC
In a phase II/III trial (NRG-CC003) reported in the Journal of Clinical Oncology, Gondi et al found that hippocampal avoidance (HA) in prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) did not improve delayed recall failure but was associated with benefits in...
Treatment-Resistant Melanoma: Novel Checkpoint Inhibitor Combination
New research published by Phadke et al in the Journal for ImmunoTherapy of Cancer found that adding a third immune-targeting drug to existing therapies may help to shrink tumors in laboratory models of treatment-resistant melanoma. Although immunotherapeutics have improved survival for many...
Can a Mitochondrial Antioxidant Drive Metastasis?
Mounting evidence suggests that the mitochondria may be a driving force behind cancer. A new report points to the mitochondrial metabolite glutathione, highlighting its central role in helping breast cancer cells break away from the primary tumor, travel through the body, and take root in other...
Endocrine Therapy With Aromatase Inhibitor for Postmenopausal Women With Breast Cancer
In a patient-level meta-analysis reported in The Lancet, Braybrooke et al of the Early Breast Cancer Trialists’ Collaborative Group found that adding subsequent years of aromatase inhibitor treatment (AIT) for women with early estrogen receptor–positive breast cancer who had already received 5...
Case 3: Patient With Myelofibrosis on Active Treatment
This is Part 3 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
Case 2: Patient With Myelofibrosis and Anemia
This is Part 2 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of a ...
Case 1: Patient With Newly Diagnosed Post-PV Myelofibrosis
This is Part 1 of Optimizing Management of Myelofibrosis: Balancing Watchful Waiting and Early Action, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Raajit Rampal, Prithviraj Bose, and Jeanne Palmer discuss the treatment of...
PSMA PET/CT and Salvage Radiotherapy in Recurrent Prostate Cancer
Use of prostate-specific membrane antigen (PSMA) PET/CT before undergoing salvage radiotherapy was associated with an improved overall survival and biochemical recurrence–free survival compared those who did not receive PSMA PET/CT scanning in male patients with biochemically recurrent prostate...
Patient Awareness of Pharmacogenomic Testing Remains Low, ACS CAN Survey Reports
Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer Society Cancer Action Network (ACS CAN). Of the patients who did know about pharmacogenomic...
New Report Supports Overhaul of Cancer Drug Dosing
A new study calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the “maximum tolerated dose” (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies. “The Totality of the Evidence: Optimizing Dosage ...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma
The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward improved progression-free survival in second-line classical Hodgkin lymphoma, according to Yuankai Shi,...
Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?
The results of a cohort study published in JAMA Network Open revealed an epidemiologic association between postmastectomy implant-based breast reconstruction for any breast tumor and both B- and T-cell non-Hodgkin lymphomas of the breast. According to Kinslow et al, this includes diffuse large...
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2025 European Hematology Association (EHA) Congress.1 Results...
A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger
The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...
ASH Announces 2025 Hematologists to Be Honored With Top Awards and Distinguished Lectures
The American Society of Hematology (ASH) will recognize 11 hematologists who have made significant contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, on December 6–9. Rainer Storb, MD, of Fred...
ASCO Names 2025 Q1, Q2 FASCO Recipients
Launched in 2007 and formerly called the ASCO Statesman Award, the FASCO distinction honors members for their extraordinary volunteer service, engagement, and dedication to American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO). Listed here are the FASCO ...
Dendrimer-Based SN38 Nanoparticle Shows Favorable Safety and Activity in Advanced Solid Tumors
In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the safety and preliminary efficacy of DEP-SN38, a polylysine-based dendrimer-nanoparticle delivery platform for the topoisomerase 1 inhibitor SN38, in patients with advanced solid tumors. SN38 is the active...
OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight
Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally. It is the largest single donation ever made to a ...
Glioblastoma: Dual Immunotherapy Plus Radiotherapy in Newly Diagnosed MGMT-Unmethylated Disease
The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with radiation therapy and temozolomide for patients with newly diagnosed MGMT-unmethylated glioblastoma, according to phase II results of the NRG-BN007 trial...
Bridging the Gap: Stronger Primary Care Ties May Improve Cancer Survivorship
Optimal continued care for patients with cancer may require greater involvement from primary care clinicians, according to the results of an observational study published in Current Oncology. The study highlighted certain challenges in cancer care, including patient-centered coordination and...
New Drug-Releasing System Eliminates Bladder Cancer in Over 80% of Patients in a Phase II Trial
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in the phase II SunRISe-1 trial (ClinicalTrials.gov identifier NCT04640623) for individuals with high-risk non–muscle-invasive bladder cancer whose disease had previously resisted treatment. In the majority of cases, the...
EBRT With Focal Boost in Localized Prostate Cancer: 10-Year Follow-up
As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprostatic tumor in patients receiving external-beam radiotherapy (EBRT) for localized prostate cancer....
Clinically Significant Fatigue and Inflammation in Breast Cancer Survivors
Clinically significant fatigue was associated with increased inflammation in breast cancer survivors, according to study findings published in BMC Women's Health. The study authors also suggested that an increase in inflammatory markers from clinical fatigue could lead to breast cancer recurrence. ...
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
The introduction of artificial intelligence (AI) to assist colonoscopies may be linked to a reduction in the ability of endoscopists to detect adenomas in the colon without AI assistance, according to a paper published by Budzyń et al in The Lancet Gastroenterology & Hepatology. Colonoscopy...
RSNA Challenge AI Models Enhance Mammography Detection of Invasive Breast Cancer
Various artificial intelligence (AI) algorithms submitted as part of a challenge demonstrated the ability to identify different breast cancers during screening mammography, according to the results of a study published in Radiology. Ensemble models of the top submitted algorithms indicated that the ...
Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods
In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed. Study ...
Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer
In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with an overall survival benefit in patients with stage III colorectal cancer aged ≤ 70 years but not in those aged > 70 ...
